Nanoviricides Inc NNVC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
-
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
-
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
-
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
-
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
-
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
-
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
-
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
Trading Information
- Previous Close Price
- $1.61
- Day Range
- $1.47–1.63
- 52-Week Range
- $0.85–2.23
- Bid/Ask
- $1.40 / $1.60
- Shares Outstanding
- 22.98M
- Market Cap
- $34.70M
- Volume/Avg
- 249,259 / 910,236
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.nanoviricides.com
Valuation
|
Metric
|
NNVC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.48 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NNVC
|
|---|---|
Quick Ratio | 3.02 |
Current Ratio | 3.17 |
Interest Coverage | — |
Quick Ratio
NNVC
Profitability
|
Metric
|
NNVC
|
|---|---|
Return on Assets (Normalized) | −77.67% |
Return on Equity (Normalized) | −88.23% |
Return on Invested Capital (Normalized) | −89.20% |
Return on Assets
NNVC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|V&%xn< | LOCK|^rhV | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@L^W@D< | LOCK|%Q#!< | $70B | |||
| argenx SE ADR
ARGX
| LOCK|Jq<S!gz | LOCK|%V@ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|m$x^fK | LOCK|$@Y@ | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@^Mpgx^ | LOCK|q>% | $36B | |||
| Moderna Inc
MRNA
| LOCK|&Q$gC>> | LOCK|$pj | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|K&lB^gRb | LOCK|Yh$S | $25B | |||
| Incyte Corp
INCY
| LOCK|lYJ?R& | LOCK|Bb | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|x%p?nn | LOCK|vP | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|vmF%S? | LOCK|rZ! | $17B |
United States